SCHEMBL16877643

SCHEMBL16877643

C1OC2CC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10774112 0.77
SCHEMBL16553448 0.75
SCHEMBL17722835 0.75
SCHEMBL16877614 0.72
SCHEMBL258990 0.71
SCHEMBL98868 0.71
SCHEMBL7516994 0.71
SCHEMBL30806215 0.71
SCHEMBL21841460 0.70
SCHEMBL11690731 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107349-A1 HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES ANTARES THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
US-20260132129-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER GENESIS THERAPEUTICS INC (US) 2026-05-14 US disclosed
US-20260130925-A1 METHODS FOR TREATING CANCER GENESIS MOLECULAR AI INC (US) 2026-05-14 US disclosed
CN-122029160-A Method for preparing PI3K inhibitor 蝎子疗法股份有限公司 2026-05-12 CN disclosed
US-20260125366-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4727938-A1 BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
US-20260106218-A1 POLYMER ELECTROLYTE AND ELECTROCHEMICAL DEVICE COMPRISING SAME FACTORIAL INC (US) 2026-04-16 US disclosed
US-12595264-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-04-07 US disclosed
EP-4705281-A1 COMPOUNDS FOR TREATING CANCER Genesis Molecular AI, Inc. (US) 2026-03-11 EP disclosed
WO-2020252240-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2020-12-17 WO disclosed
WO-2020243519-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2020-12-03 WO disclosed
WO-2020236586-A1 N-HETARYL-SQUARAMIDE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2020-11-26 WO disclosed
WO-2020150417-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2020-07-23 WO disclosed
WO-2020150439-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2020-07-23 WO disclosed
WO-2020131627-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA INC. (US) 2020-06-25 WO disclosed
WO-2020131674-A1 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER ARRAY BIOPHARMA INC. (US) 2020-06-25 WO disclosed
US-20200172534-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2020-06-04 US disclosed
US-20160326157-A1 MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-11-10 US disclosed
WO-2015103583-A1 MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-07-09 WO disclosed